Want to see SE:SPAGO full AI Analyst Report?

Spago Nanomedical AB (SPAGO) Price & Analysis

1 Followers

SPAGO Stock Chart & Stats

kr0.12

kr0.00(0.00%)

At close: Aug 12 4:00 PM EDT

kr0.12

kr0.00(0.00%)

Day’s Range― - ―

52-Week Rangekr0.08 - kr0.26

Previous CloseN/A

Volume345.89K

Average Volume (3M)225.00K

Market Cap

kr79.04M

Enterprise Valuekr44.74

Total Cash (Recent Filing)kr32.51M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.86

Next Earnings

Nov 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding798,380,100

10 Day Avg. Volume207,128

30 Day Avg. Volume225,000

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)1.42

Price to Sales (P/S)99.92

P/FCF Ratio-1.53

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.07

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance SheetZero debt limits interest obligations and refinancing exposure, giving the company greater flexibility while it develops its oncology pipeline. This conservative financing profile can help preserve strategic options and reduce balance-sheet stress during a prolonged development period.

Proprietary Oncology PlatformA proprietary nanomedicine platform focused on cancer imaging and targeted therapy gives Spago a defined technological focus and the potential to address important oncology needs. Progress across related applications could support platform value beyond a single product.

Losses Have NarrowedNarrowing annual losses indicate some improvement in financial discipline or development economics compared with earlier periods. Although the company remains loss-making, continued reduction in losses could extend funding capacity and improve operating leverage if revenue eventually scales.

Bears Say

Minimal Declining RevenueExtremely small and sharply declining revenue shows that the business has not yet achieved meaningful commercial scale. This limits internally generated funding, leaves results highly sensitive to development progress, and makes future financial performance dependent on successful commercialization.

Persistent Cash BurnPersistent operating and free-cash-flow deficits show that the company is not self-funding its activities. Continued cash consumption creates ongoing financing needs and could constrain investment in the pipeline if revenue growth or access to capital does not improve.

Shrinking Equity CushionThe substantial reduction in equity reflects sustained losses or capital-structure changes and leaves a much smaller financial cushion than in earlier periods. A reduced equity base can limit resilience, increase reliance on future funding, and amplify the impact of continued losses.

SPAGO FAQ

What was Spago Nanomedical AB’s price range in the past 12 months?

Spago Nanomedical AB lowest stock price was kr0.08 and its highest was kr0.26 in the past 12 months.

What is Spago Nanomedical AB’s market cap?

Spago Nanomedical AB’s market cap is kr79.04M.

When is Spago Nanomedical AB’s upcoming earnings report date?

Spago Nanomedical AB’s upcoming earnings report date is Nov 05, 2026 which is in 47 days.

How were Spago Nanomedical AB’s earnings last quarter?

Spago Nanomedical AB released its earnings results on Aug 20, 2026. The company reported -kr0.011 earnings per share for the quarter.

Is Spago Nanomedical AB overvalued?

According to Wall Street analysts Spago Nanomedical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Spago Nanomedical AB pay dividends?

Spago Nanomedical AB does not currently pay dividends.

What is Spago Nanomedical AB’s EPS estimate?

Spago Nanomedical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Spago Nanomedical AB have?

Spago Nanomedical AB has 798,380,100 shares outstanding.

What happened to Spago Nanomedical AB’s price movement after its last earnings report?

Spago Nanomedical AB reported an EPS of -kr0.011 in its last earnings report. Following the earnings report the stock price went up 3.448%.

Which hedge fund is a major shareholder of Spago Nanomedical AB?

Currently, no hedge funds are holding shares in SE:SPAGO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Spago Nanomedical AB

Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to pioneering nanomedicines for both the diagnosis and treatment of cancer. The company is actively pursuing two key projects: the SpagoPix initiative, centered on SN132D, a gadolinium-free MRI contrast agent developed for imaging breast and pancreatic cancers; and the Tumorad project, which is advancing SN201, a radionuclide therapy intended for managing advanced and metastatic forms of cancer. Originally established as Spago Imaging AB (publ), the company adopted its current name, Spago Nanomedical AB (publ), in May 2014. Founded in 1999, its base of operations is situated in Lund, Sweden.